 | | Vol. 5.38 – 15 October, 2021 |
| |
|
|
| Scientists analyzed somatic mutations from 1,590 genomes across 34 liver samples, including healthy controls, alcohol-related liver disease and non-alcoholic fatty liver disease. Seven of the 29 patients with liver disease had mutations in FOXO1, the major transcription factor in insulin signaling.
[Nature] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| CircIPO11 was highly expressed in hepatocellular carcinoma (HCC) tumor tissues and liver cancer stem cells (CSCs), and was required for the self-renewal maintenance of liver CSCs to initiate HCC development.
[Molecular Cancer] |
|
|
|
| Researchers showed that p53 functioned to support repair and recovery from CCl4-mediated liver damage, controlled reactive oxygen species and limited the development of hepatocellular carcinoma, in part through the activation of a detoxification cytochrome P450, CYP2A5.
[Cell Death & Differentiation] |
|
|
|
| Investigators characterized the critical factors determining the efficacy and durability of AAV/CRIPSR-mediated gene editing in dealing with complicated hepatic monogenic disorders.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Gain- and loss-of-function studies demonstrate that phosphoenolpyruvate carboxykinase 1 (PCK1) suppressed hepatocellular carcinoma (HCC) metastasis in vitro and in vivo. Specifically, lysine acetyltransferase 5 (KAT5) was highly modified by O-GlcNAcylation in PCK1 knockout hepatoma cells.
[Oncogene] |
|
|
|
| The authors demonstrated that the oncogenic protein Chromodomain-helicase-DNA-binding-protein 1-like gene (CHD1L) might have promoted hepatocellular carcinoma cells migration and metastasis through autophagy.
[Cell Death & Disease] |
|
|
|
| Liver-specific Sirutin 2 (SIRT2) deficiency sensitized mice to alcoholic liver disease, whereas transgenic SIRT2 overexpression in hepatocytes significantly prevented ethanol-induced liver injury via normalization of hepatic steatosis, lipid peroxidation, and hepatocyte apoptosis.
[Cell Discovery] |
|
|
|
| Investigators showed that golgi protein 73 (GP73) increased the secretion of alpha fetoprotein (AFP) through direct binding to AFP, thereby promoting the proliferation and metastasis of hepatocellular carcinoma cells that expressed AFP and its receptor.
[Oncogenesis] |
|
|
|
| TBX3 mutant human PSC lines were generated using CRISPR/Cas9 genome editing. TBX3 loss led to impaired liver differentiation and an upregulation of pancreatic gene expression, including PDX1, during a hepatocyte differentiation protocol.
[Stem Cell Reports] |
|
|
|
| Researchers applied long-read sequencing to precisely elucidate the hepatitis B virus (HBV) integration pattern in the human hepatocellular genome.
[NPJ Genomic Medicine] |
|
|
|
| Scientists investigated whether fibroblast growth factor 21 (FGF21) was involved in the therapeutic effect of sulforaphane against non-alcoholic fatty liver disease.
[Acta Pharmacologica Sinica] |
|
|
|
| The authors reported that depletion of mitochondrial DNA, pharmacologic inhibition of mitochondrial electron transport chain (mETC) complex I/complex III, or genetic of mETC complex I restricted cancer cell growth and clonogenicity in various preclinical models of liver cancer.
[Cell Death Discovery] |
|
|
|
| Investigators evaluated the effectiveness and safety of sintilimab, a programmed cell death protein-1 blockade, combined with sorafenib and transhepatic arterial chemotherapy and embolization in patients with unresectable hepatocellular carcinoma.
[Scientific Reports] |
|
|
|
|
| LINC00662 can reduce the promoter methylation level of s-adenosylmethionine-dependent hepatocellular carcinoma-promoting genes by regulating the MAT1A/SAM and AHCY/SAH axes, thereby promoting the activation of oncogenes. Scientists summarize the molecular regulation mechanism of LINC00662.
[Journal of Cellular Physiology] |
|
|
|
| The authors describe the mechanism of the succinate–GPR91 signaling pathway in NASH and summarize the drugs that act on this pathway, with the aim of providing a new approach to NASH treatment.
[Biomedicine & Pharmacotherapy] |
|
|
|
|
| Hansoh Pharmaceutical Group Co, Ltd and OliX Pharmaceuticals, Inc. announced a licensing and collaboration agreement to discover, develop and commercialize siRNA therapeutics in key targeted indications in Greater China, which includes mainland China, Taiwan, Hong Kong and Macau.
[Hansoh Pharmaceutical Group Co, Ltd (GlobeNewswire, Inc.)] |
|
|
|
|
| November 8 – 10, 2021
Virtual |
|
|
|
|
|
| | National Institutes of Health – Bethesda, Maryland, United States |
|
|
|
| | Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | University of Cambridge – Cambridge, England, United Kingdom |
|
|
|
| | Novo Nordisk – Indianapolis, Indiana, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
